Ozempic vs Mounjaro: Which and For Whom

Ozempic and Mounjaro get lumped together as “the GLP-1 drugs,” but they aren’t the same molecule, and the evidence supporting them isn’t identical either. Ozempic is semaglutide, made by Novo Nordisk. Mounjaro is tirzepatide, made by Eli Lilly. Both are approved for type 2 diabetes — the obesity versions of these same molecules are sold as Wegovy and Zepbound, respectively. The comparison people actually want to make, though, is which underlying drug does more, and for whom that matters.

Walnut, nut, brown — illustrating Ozempic vs Mounjaro: Which and For Whom

Different receptors, one shared idea

Semaglutide is a GLP-1 receptor agonist: it mimics a single incretin hormone to boost glucose-dependent insulin release, slow gastric emptying, and reduce appetite signaling in the brain. Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The added GIP activity appears to amplify the metabolic effect, though the exact mechanism by which GIP contributes to weight loss in humans is still being worked out; some of the clearest evidence for synergy comes from animal and mechanistic studies rather than a fully settled human explanation.

Both drugs are weekly subcutaneous injections. Both are titrated slowly upward over weeks to limit gastrointestinal side effects. Both require lifestyle changes to sustain results, and both are studied primarily in combination with diet and exercise counseling, not as a substitute for it.

What the head-to-head trial found

The best direct comparison is SURMOUNT-5, a trial that put semaglutide and tirzepatide against each other (using the obesity-indicated doses, i.e., the Wegovy and Zepbound regimens) in adults with obesity or overweight. The result favored tirzepatide: participants on tirzepatide lost roughly 20% of body weight on average, compared to roughly 14% on semaglutide, over the trial period. That’s a meaningful average gap, and it’s consistent with the broader pattern seen across each drug’s separate trial programs — the SURMOUNT program for tirzepatide has generally reported larger average weight-loss percentages than the STEP program for semaglutide.

A roughly six-point gap in average weight loss is real, but it describes the middle of a distribution — plenty of individuals on semaglutide outperformed the tirzepatide average, and plenty on tirzepatide underperformed it.

Where semaglutide still leads: cardiovascular outcomes

Weight loss isn’t the only outcome that matters, and here semaglutide has an advantage in the evidence, at least for now. The SELECT trial tested semaglutide specifically for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, without diabetes, and found a reduction in major adverse cardiovascular events (MACE). That result led to an added FDA indication for semaglutide covering cardiovascular risk reduction in this population.

Tirzepatide does not yet have an equivalent, completed outcomes trial of that scale reported. Cardiovascular and other longer-term outcome studies for tirzepatide are underway, but as of now the cardiovascular risk-reduction claim on the label belongs to semaglutide, not tirzepatide. This is a case where “newer and more effective for weight” does not automatically mean “more evidence overall” — the two drugs are simply at different points in their respective evidence lifecycles.

Broccoli, vegetables, healthy — illustrating Ozempic vs Mounjaro: Which and For Whom

Tolerability and practical differences

Both drugs share the same class of gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — most pronounced during dose escalation and typically easing over time. Trial-level comparisons haven’t shown one drug to be dramatically better tolerated than the other; discontinuation rates for GI side effects are broadly similar, though individual tolerance varies considerably and isn’t reliably predictable from mechanism alone.

Cost and access differ more sharply than tolerability. List prices for both drugs are high, insurance coverage depends heavily on diagnosis (diabetes coverage is generally more consistent than obesity coverage), and both molecules have experienced supply shortages at different points, which has shaped which one a given patient could actually obtain regardless of preference.

A decision table, held loosely

	Ozempic (semaglutide)	Mounjaro (tirzepatide)
Mechanism	GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
Approved use shown	Type 2 diabetes	Type 2 diabetes
Obesity-label sibling	Wegovy	Zepbound
Head-to-head weight loss (SURMOUNT-5, obesity doses)	~14% average	~20% average
Cardiovascular outcomes evidence	Established (SELECT trial)	Still accumulating
Tolerability	GI side effects, dose-dependent	GI side effects, dose-dependent, broadly similar
Cost/access	Varies by plan and diagnosis	Varies by plan and diagnosis

Corn, corn on the cob, corn kernels — illustrating Ozempic vs Mounjaro: Which and For Whom

Why “which is better” is the wrong first question

Population averages from trials like SURMOUNT-5 are useful for setting expectations, but they don’t predict any individual’s response. Some people lose more weight on semaglutide than the tirzepatide average; some plateau early on tirzepatide and would have done better on the other drug or a different dose. Prior response to a GLP-1 drug, tolerance of nausea, diabetes status, cardiovascular history, and what a person’s insurance will actually pay for all matter more, in practice, than which molecule has the better average in a trial. A clinician weighing a patient’s cardiovascular history against SELECT’s findings, for instance, may reasonably favor semaglutide even if tirzepatide would likely produce more weight loss.

The takeaway

Tirzepatide currently outperforms semaglutide on average weight loss in head-to-head data, and semaglutide currently has the stronger cardiovascular outcomes evidence. Neither fact settles which drug is right for a given person — that depends on medical history, tolerability, and access, and it’s a decision to make with a prescriber, not from a trial’s topline number.